GlassScriptPhysician profile
Geula Madani-Becker
NPI 1619991460
$3,464.08
in general payments reported to CMS, 2019-2025
29 companies · $584 in 2025
The $584 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $367 · 2021: $435 · 2022: $657 · 2023: $663 · 2024: $559 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,773 · Entertainment: $32.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,773.01 |
| Entertainment | $32.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $730.10 | 2019-2025 | Clareon, Rocklatan, Tryptyr |
| Novartis Pharmaceuticals Corporation | $505.83 | 2019-2023 | |
| Abbvie INC. | $180.23 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $180.06 | 2022-2025 | Acthar |
| Dompe US, INC. | $178.88 | 2022-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $173.06 | 2022-2025 | Xiidra, Miebo |
| Horizon Therapeutics Plc | $158.84 | 2021-2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $152.13 | 2019-2025 | |
| Sight Sciences, INC. | $118.71 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Kala Pharmaceuticals, INC. | $116.62 | 2020-2021 | |
| Allergan, INC. | $114.14 | 2020-2022 | |
| Amgen INC. | $94.38 | 2024-2025 | Tepezza |
| Harrow Eye, LLC | $91.13 | 2025 | Vevye |
| Oyster Point Pharma, INC. | $83.33 | 2022-2025 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $74.42 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $61.12 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Glaukos Corporation | $59.87 | 2023 | |
| Johnson & Johnson Vision Care, INC. | $55.81 | 2024 | |
| Ocular Therapeutix, INC. | $53.39 | 2022-2025 | Dextenza |
| Nova Eye, INC. | $44.79 | 2025 | |
| Eyevance Pharmaceuticals LLC | $42.56 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $37.32 | 2024 | Xdemvy |
| Optos, INC. | $32.95 | 2024-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Biotissue Holdings INC. | $25.00 | 2024 | |
| Aerie Pharmaceuticals, INC. | $22.99 | 2021 | |
| Shire North American Group INC | $20.98 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Thea Pharma INC. | $18.80 | 2022 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geula Madani-Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.